We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+13.4%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$10.9B
AUM Growth
+$1.67B
(+18%)
Cap. Flow
+$806M
Cap. Flow
% of AUM
7.42%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
678
New
211
Increased
171
Reduced
126
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ERF
Enerplus Corporation
ERF
|
+$91.2M |
| 2 |
TE Connectivity
TEL
|
+$81.6M |
| 3 |
Palo Alto Networks
PANW
|
+$78.9M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$75.6M |
| 5 |
Honeywell
HON
|
+$70.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$113M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$88.1M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$70.1M |
| 5 |
Synopsys
SNPS
|
+$64.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.5% |
| 2 | Technology | 22.75% |
| 3 | Industrials | 9.82% |
| 4 | Energy | 8.34% |
| 5 | Consumer Discretionary | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Alto Neuroscience
ANRO
$1.11B
| $1.92M | 0.02% |
+125,000
| New | +$1.96M |
|
427
Erasca
ERAS
$6.34B
| $1.84M | 0.02% |
890,793
-28,326
| -3% | -$56.6K |
|
|
FNA
428
DELISTED
Paragon 28, Inc.
FNA
| $1.79M | 0.02% |
144,676
-355,796
| -71% | -$4.23M |
|
429
ArriVent BioPharma
AVBP
$1.44B
| $1.79M | 0.02% |
+100,000
| New | +$2.02M |
|
|
KALV
430
DELISTED
KalVista Pharmaceuticals
KALV
| $1.78M | 0.02% |
150,462
-196,401
| -57% | -$2.62M |
|
|
LBPH
431
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.75M | 0.02% |
+80,920
| New | +$1.76M |
|
|
XOMA
432
DELISTED
Xoma
XOMA
| $1.73M | 0.02% |
72,106
+21,547
| +43% | +$483K |
|
433
Adicet Bio
ACET
$74.1M
| $1.73M | 0.02% |
+45,943
| New | +$1.9M |
|
434
Smith Douglas Homes
SDHC
$117M
| $1.7M | 0.02% |
+57,111
| New | +$1.6M |
|
435
Praxis Precision Medicines
PRAX
$10.3B
| $1.66M | 0.02% |
+27,263
| New | +$1.22M |
|
436
Sagimet Biosciences
SGMT
$540M
| $1.63M | 0.02% |
300,170
+1
| +0% | +$7 |
|
437
Kulicke & Soffa
KLIC
$4.74B
| $1.61M | 0.01% |
+32,099
| New | +$1.61M |
|
438
Corbus Pharmaceuticals
CRBP
$180M
| $1.61M | 0.01% |
+40,981
| New | +$1.01M |
|
439
Trex
TREX
$4.93B
| $1.59M | 0.01% |
15,976
-30,395
| -66% | -$2.71M |
|
440
Seres Therapeutics
MCRB
$47.9M
| $1.58M | 0.01% |
102,294
+37,780
| +59% | +$815K |
|
441
Fractyl Health
GUTS
$109M
| $1.56M | 0.01% |
+210,963
| New | +$1.78M |
|
442
Pliant Therapeutics
PLRX
$65M
| $1.49M | 0.01% |
100,143
-23,947
| -19% | -$395K |
|
443
Amylyx Pharmaceuticals
AMLX
$2.69B
| $1.49M | 0.01% |
523,772
+52,971
| +11% | +$693K |
|
444
Stoke Therapeutics
STOK
$2.06B
| $1.44M | 0.01% |
106,904
+50,000
| +88% | +$303K |
|
445
Stryker
SYK
$129B
| $1.35M | 0.01% |
3,759
-158,294
| -98% | -$53.3M |
|
446
Eledon Pharmaceuticals
ELDN
$267M
| $1.34M | 0.01% |
651,939
-37,401
| -5% | -$66.7K |
|
447
Coherus Oncology
CHRS
$194M
| $1.28M | 0.01% |
535,439
+35,439
| +7% | +$87.2K |
|
|
BLUE
448
DELISTED
bluebird bio
BLUE
| $1.25M | 0.01% |
48,758
+23,751
| +95% | +$609K |
|
449
Atara Biotherapeutics
ATRA
$74.3M
| $1.23M | 0.01% |
+70,992
| New | +$1.26M |
|
450
Caribou Biosciences
CRBU
$163M
| $1.22M | 0.01% |
237,277
-903,394
| -79% | -$5.57M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Woodline Partners held 678 positions worth $10.9B, up 18% from $9.2B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Woodline Partners deployed $806M of net new capital in Q1 2024, opening 211 new positions and adding to 171 existing holdings. Its largest new stake was Enerplus Corporation: 5,602,613 shares worth $110M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $110M trimmed.
- Woodline Partners's largest Q1 2024 buy was Enerplus Corporation: 5,602,613 shares worth $110M.
- Woodline Partners added most to TE Connectivity in Q1 2024, an estimated $81.6M increase.
- Woodline Partners's biggest Q1 2024 reduction was AbbVie, cutting an estimated $110M.
- Woodline Partners fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $113M.
- Woodline Partners's ten largest holdings make up 14% of its $10.9B portfolio in Q1 2024.
- Woodline Partners opened 211 new positions and closed 150 in Q1 2024.
- Woodline Partners's portfolio value rose 18% quarter-over-quarter to $10.9B.
Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.